Takeda, Astellas, Shimadzu Join To Develop iPS-Based Drugs
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical, Astellas Pharma and Shimadzu have signed an agreement with Kyoto University to develop ways to use stem cells created from adult skin in Japan. University investigators have produced pluripotent stem cells from skin. The cells are capable of growing into nerves and muscles, important in advancing regenerative medicine. Under the four-party agreement, the two drug makers are to use medical-equipment maker Shimadzu's laboratory equipment to test their drug compounds for effectiveness and toxicity, with the hope of using the iPS cells to develop new drugs within five years. (Click here for more - a subscription may be required
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.